Recordati announces that its subsidiary Orphan Europe and Erytech Pharma, a late development stage French biopharmaceutical company focused on orphan oncology and rare diseases, have entered into an agreement granting Orphan Europe the exclusive rights for the commercialization and distribution of Graspa® for the treatment of Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) in Europe.
More Info:
www.marketwire.com/press-release/recordati-licenses-graspar-from-erytech-in-europe-milan-rec-1729548.htm
No comments:
Post a Comment